Large studies, primarily from Western Europe, the U.S. and Australia, have found that potent combination anti-HIV therapy (commonly called ART or HAART) has led to tremendous improvement in the health of HIV-positive people. In Canada and other high-income countries, AIDS-related infections are uncommon for HIV-positive people who are in care and who are taking ART. As a result, researchers increasingly expect that a young adult who is infected with HIV today and who begins ART shortly thereafter and who takes his or her medicine every day exactly as directed and who does not have untreated co-existing health issues -- such as addiction, depression, schizophrenia, co-infection with hepatitis C virus -- is likely to live for several decades.
Until recently, analyses of life expectancy for large numbers of HIV-positive people in Canada and the U.S. were not available. Now a consortium of researchers across the continent has pooled health-related data collected from HIV-positive people and analysed their life expectancy. The researchers found that overall the life expectancy for HIV-positive people has increased over the past decade and is approaching that of HIV-negative people. However, not all key groups affected by HIV are experiencing the same degree of life expectancy. In this bulletin we explain which groups are affected and offer possible reasons for the observed differences.
Researchers across North America with the NA-ACCORD database analysed health-related information from 22,937 participants who initiated ART between January 1, 2000 and December 31, 2007.
The average profile of participants was as follows:
Participants were distributed across the following age ranges:
Route of infection
CD4+ count at the time ART was initiated:
A total of 1,622 people died during the study; details about causes of death were not provided.
In general, rates of death were high among groups of people with the following features/characteristics:
Based on its analysis, the research team predicted that the average life expectancy of a 20-year-old person in the U.S. or Canada who began ART shortly after he or she became HIV positive should be around 70. However, this is just an average figure, and some groups will have shorter or longer life expectancy. Below are the estimated life expectancies of a 20-year-old person in different groups in 2009, starting with HIV-negative people for comparison. At the end of the figures we provide possible explanations for these results:
Route of infection
CD4+ count when ART was initiated
These life expectancies should be compared to the time before ART became available when, on average, HIV-positive people in high-income countries lived for between 10 and 12 years after diagnosis.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.